重组人干扰素α2b阴道泡腾片治疗宫颈高危型HPV感染的疗效分析

Efficacy of Recombinant Human Interferon α2b Vaginal Effervescence Tablet in the Treatment of High Risk HPV Infection in Cervix

目的探讨重组人干扰素α2b阴道泡腾片治疗宫颈高危型人乳头瘤病毒(HPV)感染的临床疗效。方法方便选取2016年6月—2017年4月该院收治的115例宫颈高危型HPV感染患者为研究对象,依据治疗方法不同分为实验组(重组人干扰素α2b阴道泡腾片,58例)和对照组(定期随访观察不做处理,57例)。疗程结束后,统计2组HPV转阴率,观察实验组用药不良反应。结果实验组HPV总转阴率(68.97%)明显高于对照组(21.05%),差异有统计学意义(P<0.05),患者用药无明显不适,不良反应率0.00%。结论重组人干扰素α2b阴道泡腾片治疗宫颈高危型HPV感染疗效良好且无明显副作用,应用安全,值得推广。

Objective This paper tries to investigate the clinical effect of recombinant human interferon α2 b vaginal effervescence tablet in the treatment of high risk human papillomavirus（HPV） infection. Methods 115 cases of cervical highrisk HPV infection patients from June 2016 to April 2017 were convenient selected and divided into the experimental group（recombinant human interferon α2 b vaginal effervescent tablets, 58 cases） and the control group（regular follow-up, 57 cases）, after the treatment, the HPV negative rate and adverse reaction of the two groups were compared. Results The total negative rate of HPV in the experimental group was 68.97%, significantly higher than that in the control group of 21.05%,the difference was statistically significant（P〈0.05）, the patients had no obvious discomfort, and the adverse reaction rate was0.00%. Conclusion Recombinant human interferon α2 b vaginal effervescent tablets in the treatment of cervical high-risk HPV infection has good curative effect and no obvious side effects. It is safe and worthy to be popularized.